APVO
NASD Aptevo Therapeutics, Inc.$1.76 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.76, $0.04 below the day’s high of $1.80
- YTD change
- -81.34%
- vs 20-day SMA
- -3.18%
- vs 200-day SMA
- -68.27%
Price ranges
Price & Performance
-2.48 (-58.49%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $287,179.00
- APVO is down 81% since the beginning of the year
- APVO is down 93% over the past 12 months
- APVO is down 32% over the past 1 month
- 8% of all APVO investors are betting against APVO
APVO reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +24.8%.
- Previous minute
- +$0.00
- Last hour
- -$0.02
- Last 5 days
- -3.83%
- vs 8-day SMA
- -4.93%
No alerts for APVO in the last day.
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
